Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Karyopharm Therapeut (KPTI)

Karyopharm Therapeut (KPTI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Karyopharm Announces $30 Million Private Placement with RA Capital PR Newswire - Tue Mar 24, 6:01AM CDT

NEWTON, Mass. , March 24, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it has...

KPTI : 5.21 (-4.23%)
Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Met First Co-Primary Endpoint, Demonstrating Statistically Significant Improvement in Spleen Volume Reduction PR Newswire - Tue Mar 24, 6:00AM CDT

– While Similar Symptom Improvement Was Observed Across the Two Arms Relative to Baseline, SENTRY Did Not Meet its Second Co-Primary Endpoint of Abs-TSS –

KPTI : 5.21 (-4.23%)
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire - Mon Mar 2, 3:05PM CST

NEWTON, Mass. , March 2, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company...

KPTI : 5.21 (-4.23%)
Karyopharm Therapeutics: Q4 Earnings Snapshot AP - Thu Feb 12, 6:47AM CST

Karyopharm Therapeutics: Q4 Earnings Snapshot

KPTI : 5.21 (-4.23%)
Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress PR Newswire - Thu Feb 12, 6:30AM CST

–  Top-Line Data from the Phase 3 SENTRY Trial in Myelofibrosis on Track for March 2026 –

KPTI : 5.21 (-4.23%)
Karyopharm to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026 PR Newswire - Thu Feb 5, 6:30AM CST

-- Conference Call Scheduled for Thursday, February 12, 2026, at 8:00 a.m. ET --

KPTI : 5.21 (-4.23%)
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire - Mon Feb 2, 3:05PM CST

NEWTON, Mass. , Feb. 2, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company...

KPTI : 5.21 (-4.23%)
Karyopharm Announces Preliminary Unaudited 2025 Revenue and Reiterates Expectation of Delivering Potentially Transformative Phase 3 Data in 2026 PR Newswire - Mon Jan 12, 6:00AM CST

– Top-Line Data from the Phase 3 SENTRY Trial in Myelofibrosis on Track for March 2026 –

KPTI : 5.21 (-4.23%)
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire - Fri Jan 2, 3:05PM CST

NEWTON, Mass. , Jan. 2, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company...

KPTI : 5.21 (-4.23%)
Breakthrough ASH Data Drives Blood Cancer Market To $240B Valuation BayStreet.ca - Thu Dec 11, 2025

Issued on behalf of GT Biopharma, Inc. VANCOUVER – Baystreet.ca News Commentary – The 2025 American Society of Hematology meeting showcased pivotal advances in blood cancer treatment, with...

PTGX : 104.31 (+3.90%)
KPTI : 5.21 (-4.23%)
GTBP : 0.4650 (-2.13%)
GSK : 54.70 (+3.31%)
TAK : 18.29 (+1.39%)

Barchart Exclusives

Williams-Sonoma Just Raised Its Dividend 15%. Should You Buy the Blue-Chip Stock Here? Barchart - Wed Mar 25, 6:30PM CDT
Williams-Sonoma is rewarding shareholders with a 15% dividend hike and steady execution. Does this consistency leave upside on the table? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.